* If you want to update the article please login/register
A phase II clinical trials test the safety and effectiveness of an investigational drug to see if the drug can be used to treat a specific disease. BVD-523 has been tested in patients with solid tumors to determine the highest dose of BVD-523 that can be safely administered to patients. In this research report, the investigators are investigating the role of BVD-523 in the care of patients with uveal melanoma. Genetic mutations in metastatic uveal melanoma trigger proteins in the MAPK protein signaling pathway, which leads to tumor formation.
Source link: https://clinicaltrials.gov/ct2/show/NCT03417739
In patients with metastatic uveal melanoma, the primary response rate to vorinostat is unknown. To determine the overall objective response rate in patients with metastatic uveal melanoma. In patients with metastatic uveal melanoma, it's likely that vorinostat has tolerability in patients with metastatic uveal melanoma. To discuss the change of circulating cell-free, tumor-derived deoxyribonucleic acid levels measured by pyrophosphorolysis stimulated polymerization in plasma of patients under diagnosis of metastatic uveal melanoma. To measure overall target RR with GNAQ, GNA11, SF3B1, and BAP1 mutation status, V. To compare overall objective RR with GNAQ, GF11, SF3B1, and BAP1 mutation status. OUTLINE: Patients receive vorinostat orally twice a week for four weeks, and patients are exposed to vorinostat orally twice a week for three days.
Source link: https://clinicaltrials.gov/ct2/show/NCT01587352
In patients with metastatic uveal melanoma, the investigator will investigate the potential effectiveness of the combination of defactinib hydrochloride and Raf/MEK serine/threonine kinase inhibitor RO5126766. In patients with metastatic uveal melanoma, it is possible to determine the effectiveness of defactinib in combination with VS-6766. Patients are defactinib orally twice a day and VS-6766 PO twice a week for three weeks in every cycle. Patients are followed every 3 months until death, or up to two years after the last patient is enrolled, after completion of study research.
Source link: https://clinicaltrials.gov/ct2/show/NCT04720417
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions